Immunome Inc. 8-K

What Happened

• Immunome, Inc. filed an 8-K on June 12, 2026 reporting final results from its 2026 Annual Meeting of Stockholders held June 9, 2026 (record date April 16, 2026; 113,249,519 shares outstanding).
• Stockholders elected three Class III directors — James Boylan, Sandra Swain, M.D., and Philip Wagenheim — each to serve until the 2029 Annual Meeting. The meeting also ratified Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2026 and approved advisory votes on executive compensation and the frequency of those advisory votes.

Key Details

• Director election results: James Boylan — 70,209,570 votes for, 22,171,996 withheld, 11,768,578 broker non-votes; Sandra Swain — 92,157,301 for, 224,265 withheld, 11,768,578 broker non-votes; Philip Wagenheim — 92,162,632 for, 218,934 withheld, 11,768,578 broker non-votes.
• Auditor ratification: Ernst & Young LLP ratified with 104,100,900 votes for, 27,134 against, 22,110 abstentions.
• Advisory vote on executive compensation (say-on-pay): approved 90,908,436 for, 1,442,116 against, 31,014 abstentions; 11,768,578 broker non-votes.
• Advisory vote on frequency: stockholders favored annual votes — 91,949,591 for 1 year, 368,407 for 2 years, 41,534 for 3 years; Company will hold advisory votes on executive compensation every year going forward.

Why It Matters

• Board continuity: Election of the three Class III directors keeps the current Board leadership in place through the 2029 meeting, which affects governance and strategic oversight.
• Audit oversight: Ratification of Ernst & Young LLP confirms the auditor for fiscal 2026, important for financial reporting and audit continuity.
• Shareholder feedback on pay: The strong approval of the company’s named executive officer compensation (and preference for annual advisory votes) signals investor support for current pay practices and commits the company to yearly say-on-pay votes (though the advisory vote itself is non‑binding).